Recent Announcements

What's New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Where applicable, all regimens have been reordered by pan-genotypic activity, level of evidence, and alphabetically. Updated references have been provided throughout the guidance where appropriate. Sections of the guidance where key updates occurred are listed below.

Initial Treatment of Adults with HCV Infection & Patients With HIV/HCV Coinfection

Read More

What’s New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred are listed below:

Monitoring

  • This section has been updated to include guidance for patients with incomplete adherence.


Patients With HIV/HCV Coinfection:

Read More

What’s New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred are listed below:

Retreatment of Persons in Whom Prior Therapy Failed:

Read More

What’s New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred are listed below:

HCV Testing and Linkage to Care

Read More

What’s New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. All treatment sections have been updated; less efficacious, complex, alternative regimens and those no longer available in the U.S. have been removed.

Read More

What’s New, Updates, and Changes to the Guidance

This version of the guidance has been updated to reflect new testing and management recommendations for pregnant women, people who inject drugs, men who have sex with men, and people who are incarcerated.

The following new sections for management of patients with HCV in key populations have been added to the guidance:

Read More

What’s New, Updates, and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance.

In addition to updates to all the sections, the following new sections have been added to the guidance:

Read More

Glecaprevir/pibrentasvir and sofosbuvir/ velpatasvir/voxilaprevir have been approved by the FDA- update coming soon.

In addition to updates for all relevant sections in response to the new approvals, the following new sections will be released soon:

  • HCV in Children
  • HCV in Pregnancy
  • HCV Resistance Primer
     

FDA announcements:

Read More

What’s New and Updates/Changes

This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance. 

Read More

What’s New and Updates/Changes

The HCV Guidance Panel has reviewed new information that highlights the risk of HBV infection reactivation in patients who are coinfected and who clear HCV with DAAs. They have therefore chosen to alert providers. The updated information can be found in the Monitoring Patients Who Are Starting Hepatitis C Treatment, Are On Treatment, or Have Completed Therapy section of the Guidance.

Read More
Top